- Home
- CYN vs KALA Comparison
CYN vs KALA Comparison
Compare CYN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYN
- KALA
- Stock Information
- Founded
- CYN 2013
- KALA 2009
- Country
- CYN United States
- KALA United States
- Employees
- CYN N/A
- KALA N/A
- Industry
- CYN EDP Services
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- CYN Technology
- KALA Health Care
- Exchange
- CYN Nasdaq
- KALA Nasdaq
- Market Cap
- CYN 28.0M
- KALA 26.2M
- IPO Year
- CYN 2021
- KALA 2017
- Fundamental
- Price
- CYN $5.48
- KALA $17.47
- Analyst Decision
- CYN
- KALA Strong Buy
- Analyst Count
- CYN 0
- KALA 3
- Target Price
- CYN N/A
- KALA $32.67
- AVG Volume (30 Days)
- CYN 247.4K
- KALA 298.2K
- Earning Date
- CYN 11-05-2025
- KALA 11-11-2025
- Dividend Yield
- CYN N/A
- KALA N/A
- EPS Growth
- CYN N/A
- KALA N/A
- EPS
- CYN N/A
- KALA N/A
- Revenue
- CYN $434,837.00
- KALA N/A
- Revenue This Year
- CYN $31.96
- KALA N/A
- Revenue Next Year
- CYN $1,459.25
- KALA N/A
- P/E Ratio
- CYN N/A
- KALA N/A
- Revenue Growth
- CYN 445.29
- KALA N/A
- 52 Week Low
- CYN $3.62
- KALA $2.92
- 52 Week High
- CYN $1,312.50
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- CYN 44.28
- KALA 72.92
- Support Level
- CYN $5.20
- KALA $13.14
- Resistance Level
- CYN $5.57
- KALA $15.66
- Average True Range (ATR)
- CYN 0.34
- KALA 1.96
- MACD
- CYN 0.09
- KALA 0.41
- Stochastic Oscillator
- CYN 41.82
- KALA 71.93
About CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.